Characteristic | ABC/EFV/ddI (N = 24) | ABC/EFV/ddI/HU (N = 30) |
---|---|---|
Age, years | Â | Â |
   Mean ± SD | 39.5 ± 7.8 | 38.1 ± 8.4 |
   Median (Range) | 37 (29–62) | 37 (26–59) |
Gender, n (%) | Â | Â |
   Male | 21 (88) | 26 (87) |
   Female | 3 (13) | 4 (13) |
Race, n (%) | Â | Â |
   Caucasian | 13 (54) | 16 (53) |
   African American | 8 (33) | 4 (13) |
   Hispanic | 2 (8) | 7 (23) |
   Other | 1 (4) | 3 (10) |
CDC classification, n (%) | Â | Â |
   Category A | 9 (38) | 19 (63) |
   Category B | 10 (42) | 5 (17) |
   Category C | 5 (21) | 6 (20) |
HIV-1 RNA, log10 copies/mL | Â | Â |
   Mean ± SD | 3.86 ± 0.55 | 3.86 ± 0.67 |
   Median (Range) | 3.93 (2.86–4.73) | 3.90 (2.73–4.82) |
CD4 cell count, cells/mm3 | Â | Â |
   Mean ± SD | 345 ± 192 | 346 ± 167 |
   Median (Range) | 291 (67–805) | 326 (53–794) |
Prior antiretroviral treatment, n (%) | Â | Â |
   NRTIs | 24 (100) | 29 (97) |
Lamivudine | 16 (67) | 19 (63) |
Stavudine | 11 (46) | 18 (60) |
Lamivudine/zidovudine combination tablet | 10 (42) | 10 (33) |
Zidovudine | 5 (21) | 4 (13) |
Zalcitabine | 0 | 1 (3) |
   PIs | 22 (92) | 26 (87) |
Nelfinavir mesylate | 10 (42) | 17 (57) |
Indinavir sulfate | 7 (29) | 7 (23) |
Saquinavir | 3 (13) | 2 (7) |
Ritonavir | 1 (4) | 2 (7) |
Lopinavir + ritonavir | 1 (4) | 1 (3) |
Amprenavir | 1 (4) | 0 |
Premature withdrawal from study, n (%) | 10 (42) | 14 (47) |
   Adverse eventa | 1 (4) | 7 (23) |
   Consent withdrawn | 2 (8) | 0 |
   Protocol-defined virologic failure | 5 (21) | 1 (3) |
   Lost to follow-up | 1 (4) | 3 (10) |
   Protocol violation | 0 | 1 (3) |
   Other | 1 (4) | 2 (7) |